



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/847,665	05/03/2001	Ute Rogner	03495.0203	6991

22852 7590 09/30/2002

FINNEGAN, HENDERSON, FARABOW, GARRETT &  
DUNNER LLP  
1300 I STREET, NW  
WASHINGTON, DC 20006

EXAMINER

HAYES, ROBERT CLINTON

ART UNIT PAPER NUMBER

1647

DATE MAILED: 09/30/2002

9

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.

09/847,665

Applicant(s)

ROGNER ET AL.

Examiner

Robert Hayes

Art Unit

1647

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 30 October 2001.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-3, 5-7, 9-10, 15-20, 22, 24-28, 33-41, 45-49, 54-61 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-3, 5-7, 9-10, 15-20, 22, 24-28, 33-41, 45-49, 54-61 are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All b) ☐ Some \* c) ☐ None of:  
1. ☐ Certified copies of the priority documents have been received.  
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  
\* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_
- 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_

## DETAILED ACTION

### *Election/Restrictions*

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-3, 5, 9-10, and 54 drawn to a method for screening neural system defects in chromosomal material of a mammal by DNA hybridization with a labeled probe, classified in class 435, subclass 6, for example.
  - II. Claims 6-7, and 55 drawn to a method for screening neural system defects using an antibody, classified in class 435, subclass 7.1, for example.
  - III. Claims 15-20, 22, 24-26, 33-36, 40-41, 45-48, and 56-61 to polynucleotide, vectors, and cells comprising the same, classified in class 536, subclass 23.1, for example.
  - IV. Claim 27 and 37-38, drawn to a method of screening for therapeutic compounds comprising introducing to a cell a compound to be screened, classification dependent upon compound structure.
  - V. Claim 28, a method of screening for therapeutic compounds comprising introducing a compound to be screened to a transgenic knockout animal, classified in class 800, subclass 9, for example.
  - VI. Claim 39, drawn to a method of increasing the expression of *NAP1L2* gene in turmoil human neural cells or for decreasing the expression of *Nap1l2* gene in human neural cells afflicted by a degenerating disease, comprising administering a compound, classification dependent upon compound structure.

VII. Claim 49, drawn to a method for targeted expression of a polypeptide in a neural cell, classification dependent upon how expression is targeted.

2. The inventions are distinct, each from the other because of the following reasons:

3. Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive Inventions that are directed to different methods, restriction is deemed to be proper because these methods appear to constitute patentably distinct inventions for the following reasons: Inventions I, II, IV, V, VI, and VII are directed to methods that are distinct both physically and functionally, and are not required one for the other. Invention I requires search and consideration of DNA hybridization, which is not required by any of the other Inventions. Invention II requires search and consideration of screening neural system defects using an antibody, which is not required by any of the other Inventions. Invention IV requires search and consideration of method of screening for therapeutic compounds comprising introducing to a cell a compound to be screened, which is not required by any of the other Inventions. Invention V requires search and consideration of transgenic knockout animal, which is not required by any of the other Inventions. Invention VI requires search and consideration of comprising administering a compound in a therapeutic method, which is not required by any of the other Inventions. Invention VII requires search and consideration of targeted expression of a polypeptide in a neural cell, which is not required by any of the other Inventions.

4. Inventions III and each of I, IV, and VII are related as product and processes of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the processes for using the product as claimed can be practiced with another materially different

Art Unit: 1647

product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the product as claimed can be used in a materially different process of using that product. The polynucleotides, vectors, and cells of Invention III can be used in cell transplantation therapy or gene therapy.

5. Inventions III and each of II, V, and VI are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions of Inventions III and each of II, V, and VI are unrelated product and methods, wherein each is not required, one for another. For example, the claimed methods of Inventions II, V, and VI do not recite the use or production of the polynucleotides, vectors, and cells of Invention III.

6. **FURTHERMORE, restriction to one of the following inventions is required under 35 U.S.C. 121:**

- A. Claims 1-3, 5-7, 9-10, 15-20, 22, 24-28, 33-41, 45-49, and 54-61, each in part, as the inventions pertain to SEQ ID NO: 2.
- B. Claims 1-3, 5-7, 9-10, 15-20, 22, 24-28, 33-41, 45-49, and 54-61, each in part, as the inventions pertain to SEQ ID NO: 4.
- C. Claims 1-3, 5-7, 9-10, 15-20, 22, 24-28, 33-41, 45-49, and 54-61, each in part, as the inventions pertain to SEQ ID NO: 6.

7. The inventions are distinct, each from the other because of the following reasons:

Art Unit: 1647

8. Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive Inventions that are directed to different products, restriction is deemed to be proper because these products appear to constitute patentably distinct inventions for the following reasons: Inventions A, B, and C are directed to sequences that are distinct both physically and functionally, and are not required one for the other. Invention A requires search and consideration of SEQ ID NO: 1, which is not required by any of the other Inventions.

Invention B requires search and consideration of SEQ ID NO: 4, which is not required by any of the other Inventions. Invention C requires search and consideration of SEQ ID NO: 6, which is not required by any of the other Inventions. Each sequence requires a separate search of the literature and sequence databases. A search and examination of an Invention as it pertains to all sequences would therefore present the examiner with an undue search burden.

9. **Applicant is advised that this is not a requirement to elect a species. Rather, this is a second restriction requirement superimposed upon the requirement to elect one group from I-VII. In order to be fully responsive, Applicant must elect one group from I-VII and one group from A-C.**

10. This application contains claims directed to the following patentably distinct species of the claimed invention:

- a. Immortal cell line
- b. Neuronal cell line
- c. Tumor derived cell line
- d. Embryonic stem cells
- e. Wild type animal

Art Unit: 1647

11. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 19 and 58 are generic.

**12. If applicant selects either Invention II or III, one species from the neural cell group must be chosen to be fully responsive.**

13. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

14. Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

15. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

16. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Art Unit: 1647

17. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, separate search requirements, and/or different classification, restriction for examination purposes as indicated is proper.

18. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).



Art Unit: 1647


***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert Hayes whose telephone number is 703-305-3132. The examiner can normally be reached on Monday through Friday, 8:30AM to 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, Ph.D. can be reached on 703-308-4623. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-872-9307 for After Final communications. The fax phone numbers for the customer service center is 703-872-9305.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

CJN  
September 27, 2002

  
**GARY KUNZ**  
**SUPERVISORY PATENT EXAMINER**  
**TECHNOLOGY CENTER 1600**